APR 0 5 2004

PTO/SB/08a(08/03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

onder th	e Paperwork	Reduction Ac	t of 19	95, no persons are required t	to respond to a collection of information uni	mice; U.S. DEPARTMENT less it displays a valid. OME	3 control number.		
Substitute for form 1449A/PTO					Application Number	10/613,432			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Filing Date	July 3, 2003			
					First Named Inventor	Stephen A. Scaringe			
					Art Unit	1646			
(Use as many sheets as necessay)					Examiner Name	Not yet accorded			
Sheet	heet 1 of 2			2	Attorney Docket No.	DH260625 CON2			
				NON PATENT	LITERATURE DOCUMENT	rs	•		
Examiner Initials*	Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published						
Ho	1		WOJCIECH T. MARKIEWICZ, "Tetralsopropyldisiloxane-1, 3-diyl, a Group for Simultaneous Protection of 3' – and 5' – Hydroxy Functions of Nucleosides," J. Chem. Research(s), 1979, pp. 24-25						
Ho	2	SERGE pp. 222	SERGE L. BEAUCAGE, et al., "Tetrahedron Report Number 309," Tetrahedron, Vol. 48, No. 12, pp. 2223-2311, 1992						
Do	3	Related	DANIEL C. CAPALDI, et al., "Use of the 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp) and Related Protecting Groups in Oligoribonucleotide Synthesis: Stability of Internucleotide Linkages to Aqueous Acid," Nucleic Acids Research, 1994, Vol. 22 No. 12, pp. 2209-2216						
Ao	4	CHRIS CHRISTODOULOU, "Incompatibility of Acid-Labile 2' and 5' Protecting Groups For Solid – Phase Synthesis of Oligoribonucleotides," Tetrahedron Letters, 1986, Vol. 27, No. 13, pp. 1521-1522							
Ho	5	TSUJIAKI HATA, et al. "2-Chloroethyl Orthoformate as a Reagent for Protection in Nucleotides Synthesis," Tetrahedron Letters, No. 51, pp. 4443-4446, 1969							
Ho	6	J. GORI Reagen	J. GORDON HILL, et al. "Anhydrous tert – Butyl Hydroperoxide in Toluene: The Preferred Reagent for Applications Requiring Dry TBHP," J. Org. Chem., 1983, 48, pp. 3607-3608						
Ho	7	OSAMU Hamme	OSAMU ODAI, et al. "Synthesis and NMR Study of Ribooligonucleotides Forming a Hammerhead-type RNA Enzyme System," Nucleic Acids Research, Vol. 18, No. 20, pp. 5955-5960						
Ho	8	the Soli	RAO, et al., "Use of the 1-(2-Fluorophenyl)-4-Methoxypiperidin-4-yl (Fpmp) Protecting Group in the Solid-Phase Synthesis of Oligo- and Poly-ribonucleotides," J. Chem. Soc. Perkin Trans. 1993, pp. 43-55						
As	9	HIMANS Oligorib	HIMANSHU RASTOGI, et al. "A New 2'-Hydroxyl Protecting Group for the Automated Synthesis of Oligoribonucleotides," Nucleic Acids Research, 1995, Vol. 23, No. 23, pp. 4872-4877						
As	10	OSAMU SAKATSUME, et al. "Synthesis and Properties for Non-hammerhead RNA Using 1-(2-Chlorethoxy)- Ethyl Group for the Protection of 2'-Hydroxyl Function," Nueclosides & Nucleotides, 10 (1-3), 1991, pp. 141-153							
Ao	11	MITSUO SEKINE, et al. "Cyclic Orthoester Functions as New Protecting Groups in Nucleosides," J. American Chemical Society," 1983, 105, pp. 2044-2049							
EXAMINER SIGNATURE	H	T Thrond	19	Que .		DATE CONSIDERED	3-7-0	<u> </u>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	OIPE	
(B	APR 0 5 2004 SH	
B	C RA Substitute	fo

<u> </u>								
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Application Number	10/613,432		
					Filing Date	July 3, 2003		
					First Named Inventor	Stephen A. Scaringe 1646		
					Art Unit			
(Use as many she	eets as nece	essay)			Examiner Name	Not yet accorded		
Sheet	2		of	2	Attorney Docket No.	DH260625 CON2		
				NON PATENT	LITERATURE DOCUMEN	TS		
Examiner Initials*	Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published					
Ho	12	Protect	TOSHIKI TANAKA, et al. "Solid Phase Synthesis of Oligoribonucleotides Using 0-Nitrobenzyl Protection of 2'-hydroxyl via a Phosphite Triester Approach," Nucleic Acids Research, Vol. 14, Number 15, 1986, pp. 6265-6279					
Ho	13	WU et a Oligoril	WU et al. (1989) "Prevention of Chain of Cleavage in the Chemical Synthesis of 2' - Silylated Oligoribonucleotides," Nucleic Acids Research, Vol. 17, No. 9. 1989, pp.3501-3517					
A	STEPHEN A SCARINGE, et al. "Chemical Synthesis of Biologically Active Oligoribonucleotides Using β-Cyanoethyl Protected Ribonucleoside Phosphoramidites," Nucleic Acids Research, Vol. 18, No. 18, pp. 5433-5441 1990.							
	<u> </u>					,		
						·		
						•		
	-	<u> </u>					ļ	
				····				
							<u> </u>	
	-			· · · · · · · · · · · · · · · · · · ·				
	1							
EXAMINER SIGNATURE	K	mad	1	(kg)		DATE CONSIDERED 3-7-0	<u>5</u>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.